Contribute Try STAT+ Today

After months of deliberation, the Food and Drug Administration has asked all manufacturers of a particular heartburn medicine known as ranitidine, sold under several brands including Zantac, to withdraw their drugs because “unacceptable levels” of a possible carcinogen may develop in the pills over time.

Specifically, the agency determined that levels of NDMA, an organic chemical that was once used to make rocket fuel and is an unintended byproduct of certain chemical reactions, may gradually increase and can increase significantly when stored in higher heat than room temperature.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • And as the current level of “heartburn” over current events rises, another ‘player’ leaves the field. A great safety based data point to stand in counterpoint to the new …anecdotally (I didn’t say ‘magic’) based approval paradigm.

Comments are closed.